Basilea Pharmaceutica AG BPMUF

Company Overview

Basilea Pharmaceutica AG is a Swiss biopharmaceutical company focused on developing and commercializing anti-infective medicines and oncology therapies. The company operates primarily in the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on addressing serious bacterial and fungal infections and targeted cancer treatments. Basilea’s core revenue drivers include product licensing agreements, milestone payments, royalties from partnered products, and sales generated through commercialization partnerships. The company’s marketed anti-infective products include Cresemba (isavuconazole), an antifungal treatment for invasive fungal infections, and Zevtera (ceftobiprole medocaril), a broad-spectrum cephalosporin antibiotic approved in multiple jurisdictions for serious bacterial infections.

Basilea was founded in 2000 as a spin-off from Roche and is headquartered in Basel, Switzerland. Since its formation, the company has evolved from a research-focused biotechnology enterprise into a commercial-stage pharmaceutical company with global licensing and commercialization partnerships. Its strategic positioning is supported by specialization in hospital-focused anti-infectives, regulatory expertise in rare and severe infectious diseases, and collaborations with larger pharmaceutical partners for international distribution and commercialization.